Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Death Dis
Main Authors: Khamari, Raeeka, Trinh, Anne, Gabert, Pierre Elliott, Corazao-Rozas, Paola, Riveros-Cruz, Samuel, Balayssac, Stephane, Malet-Martino, Myriam, Dekiouk, Salim, Joncquel Chevalier Curt, Marie, Maboudou, Patrice, Garçon, Guillaume, Ravasi, Laura, Guerreschi, Pierre, Mortier, Laurent, Quesnel, Bruno, Marchetti, Philippe, Kluza, Jerome
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://ncbi.nlm.nih.gov/pubmed/29487283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0340-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki